IMMIX Biopharma earnings were -$39.9M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest IMMX earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$11.6M, up 14.6% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, IMMX reported annual earnings of -$29.4M, with 36.2% growth. The next IMMX earnings date is Nov 6, 2026.
What were IMMIX Biopharma's earnings last quarter?
On IMMX's earnings call on Aug 14, 2026, IMMIX Biopharma (NASDAQ: IMMX) reported Q2 2026 earnings per share (EPS) of -$0.18, up 18.18% year over year. Total IMMX earnings for the quarter were -$11.56 million. In the same quarter last year, IMMIX Biopharma's earnings per share (EPS) was -$0.22.
The next IMMX earnings call is Nov 6, 2026. Add IMMX to your watchlist to be reminded of IMMIX Biopharma's next earnings date.
Is IMMIX Biopharma profitable or losing money?
As of the last IMMIX Biopharma earnings report, IMMIX Biopharma is currently losing money. IMMIX Biopharma's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$39.92 million, a 72.6% increase year over year.
What was IMMX's earnings growth in the past year?
As of IMMIX Biopharma's earnings date in Aug 14, 2026, IMMIX Biopharma's earnings has grown year over year. IMMX earnings in the past year totalled -$39.92 million.
What are IMMIX Biopharma's earnings expectations?
The current EPS estimate for IMMIX Biopharma's earnings report in Nov 6, 2026 is -$0.18.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.